Likewise, addition of sPD-1 may also overcome resistance to anti-PD-L1 mAb as anti-PD-1 mAb shares the same targets with sPD-1 and both have shown similar in vitro anti-cancer immunity (161, 185). Here, PDCD1 is linked to cancer.